No Data
No Data
EnVVeno Medical Q1 EPS $(0.31) Beats $(0.40) Estimate
enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.40) by 22.5 percent. This is a 45.61 percent increase over losses of $(0.5
EnVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
10-Q: Quarterly report
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement From EnVVeno Medical's VenoValve(R) Pivotal Trial to Be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Pa
Express News | New Topline Efficacy Data From EnVVeno Medical VenoValve Pivotal Trial To Be Presented At 46th Annual Charing Cross Symposium On April 24, 2024
New Topline Efficacy Data From the EnVVeno Medical VenoValve(R) Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today an